Form 4: Denali Therapeutics Director Steve Krognes Reports Stock Sale

Director Steve Krognes of Denali Therapeutics reports the sale of 30,000 shares of common stock on December 31, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On December 31, 2024, Steve E. Krognes, a director of Denali Therapeutics Inc., sold 30,000 shares of common stock at a weighted average price of $20.25 per share.
• The sales were executed under a Rule 10b5-1 trading plan adopted on December 1, 2023.
• Following the transaction, Krognes directly owns 29,096 shares, including 13,467 unvested RSUs, and indirectly owns 781,797 shares through The Steve Edward Krognes Revocable Trust.
• The price range for the shares sold was between $20.10 and $20.55.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged trading plan and doesn't necessarily indicate a change in the director's confidence in the company.

Industry Context

Sales by company insiders are a common occurrence and are often related to personal financial planning rather than a reflection of the company's prospects.

Stakeholder Impact

• The sale of shares by a director could have a minor negative impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates